Alexza Pharmaceuticals up 38% on Resubmission of ADASUVE NDA

Alexza Pharmaceuticals ALXA is trading higher on the session following the announcement of a resubmission of ADASUVE NDA. The company said that in the coming weeks, it expects to hear from the FDA regarding the completeness of the resubmitted NDA. ADASUVE is being developed for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Alexza Pharmaceuticals is currently trading at $3.80, a gain of $1.06 or 38.69%.